





















Cervical cancer, a well-characterized virus-induced 
malignancy, is the second most common cause of 
cancer-related death in women [1, 2]. While the link 
between the formation of genital warts and their 
inherent propensity to progress to cancer was suspected 
more then a century ago [1], the connection between 
cervical cancer and the human papillomavirus (HPV) 
was demonstrated only two decades ago.  During the 
early 1980’s the zur Hausen laboratory provided the 
first experimental proof that the genome of malignant 
genital warts was integrated with DNA from the HPV 
subtypes 16 and 18 [3-5]. In addition to stimulating 
significant progress in delineating the molecular 
mechanisms causing cervical cancer, this observation 
led to the development of an effective vaccine that is 
now widely used in many countries [2].  However, 
while this vaccine prevents cervical cancer in ~ 70% of 
the population [6-10], it is not effective in individuals 
previously exposed to the virus [2]. Therefore, in order 
to develop effective strategies to eradicate cervical 
cancer, additional studies are needed to identify and 
characterize novel factors and cellular mechanisms 
involved in HPV-induced malignancy.  
 
It is now well established that to trigger cell 
transformation, the genome of the high-risk HPV 16 
and 18 viruses has to integrate into the DNA of host 
cells [3-5].  This integration enables the expression of 
viral proteins such as E6 and E7 which are key players 
in HPV-induced carcinogenesis as well as in the 
maintenance of the cell transformation phenotype [11, 
























suppressor mechanisms elicited by p53 and 
retinoblastoma (pRb) proteins, respectively [2].                   
Through this influence, E6 and E7 prevent infected cells 
from entering senescence, a state of irreversible cell 
cycle arrest that normally occurs at the end of the 
lifespan of the cell, in the presence of certain 
oncogenes, or following cellular damage [13].   
Additionally, E6 blocks senescence by inducing the 
expression and activation of the human telomerase 
reverse transcriptase (hTERT) [14-16].  Although the 
detailed molecular mechanisms by which E6 promotes 
malignancy are still elusive, E6 forms a complex with 
the E6-associated protein (E6-AP), a HECT ubiquitin 
protein ligase, and mediates the proteasome-dependent 
degradation of p53. Furthermore, E6-AP has been 
shown to mediate the degradation of NFX1, a 
transcriptional repressor of human telomerase reverse 
transcriptase (hTERT).  By decreasing NFX1 levels, 
E6-AP promotes the expression of hTERT, which 
consequently increases the activity of the telomerase 
complex and prevents cellular senescence [2, 17]. While 
links between transcription regulation and the 
expression of many genes involved in the development 
of cervical cancer has been described [2, 17], the effects 
of HPV infection on post-transcriptional events such as 
mRNA turnover are not known.  One of the main 
questions that remain unanswered to-date is whether 
infection by HPV negatively or positively affects the 
mRNA turnover machinery and if so, whether these 
events are linked to the development of malignant 
genital warts.  
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answer some of these questions by establishing a direct 
connection between the ability of the high-risk HPV 18 
virus to promote cell malignancy and the inability of the 
host cell to express the mRNA decay factor 
tristetraprolin (TTP) [18]. TTP is an RNA-binding 
protein that binds AU-rich elements (AREs) located in 
the 3’ untranslated region (UTR) of many unstable 
mRNAs such as those that encode tumor necrosis factor 
(TNF)-α, granulocyte/macrophage colony-stimulating 
factor (GM-CSF), IL (interleukin)-2, and cyclo-
oxygenase (Cox)-2 [19].  TTP harbors two cysteine-
cysteine-cysteine-histidine zinc-finger domains through 
which it binds to the AREs of target mRNAs, promoting 
their rapid degradation via the AMD (ARE-mediated 
mRNA decay) pathway [20].  Sanduja and colleagues 
show that TTP levels are substantially low in cervical 
carcinomas when compared to non-transformed tissue, 
wherein TTP is highly abundant in the cytoplasm.   
These observations argue for a direct link between TTP 
expression levels and the malignant potential of a cell.  
Interestingly, a recent study by the Wilson laboratory 
showed that TTP expression is low in many cancers, 
supporting its function as a tumor suppressor, and 
raising the possibility that TTP abundance could serve 
as a prognostic indicator of cancer severity and 
malignancy [21].  On the other hand, Sanduja et al. have 
observed that expressing TTP protein in cells already 
infected by HPV leads to cell cycle arrest.  They 
showed that overexpressing TTP in HeLa (human 
cervical carcinoma) cells immortalised by the HPV-18 
virus causes them to senesce as evidenced by the 
induction of senescence-associated β-galactosidase (SA 
β-gal) activity and the significant increase in p53 levels 
[18].  This effect, however, does not seem to be unique 
to cells with a potential to develop cervical cancer.  A 
recent study by the Gorospe laboratory has shown that 
the expression of TTP is increased in cultured human 
diploid fibroblasts reaching replicative senescence [22].  
As replicative senescence represents a tumor-
suppressive mechanism, these findings collectively 
suggest that preventing the expression of TTP could be 
an early event in the development of many cancers.   
Together with the fact that elevated TTP abundance 
sensitizes HeLa cells to apoptosis-causing agents such 
as staurosporine [21], TTP appears to act as a tumor 
suppressor by promoting senescence and by decreasing 
the expression of pro-apoptotic proteins. 
 
In an effort to elucidate the molecular mechanism 
through which TTP induces senescence, Sanduja and 
colleagues discovered that TTP regulates post-
transcriptionally the expression of the E6-AP mRNA 
[18].  The authors observed that TTP expression in 
HPV-transformed cells significantly decreased E6-AP 
mRNA and protein levels.  Although the E6-AP mRNA 
was quite stable in HeLa cells, it quickly decayed in the 
presence of TTP.  The ability of TTP to lower the half-
life of the E6-AP mRNA was comparable to that 
observed for other transcripts containing multiple 
3’UTR AREs, such as the TNFα mRNA [23, 24].   
Immunoprecipitation coupled to RT-qPCR experiments 
confirmed that TTP associates with the E6-AP mRNA 
in HeLa cells.  Through an elegant set of experiments, 
the authors demonstrated that TTP regulates post-
transcriptionally the E6-AP mRNA via sequences 
located in its 3’UTR.  Co-expression of TTP with 
luciferase reporter constructs that either contained or 
lacked the E6-AP 3’UTR revealed that TTP prevented 
luciferase expression in the presence of the E6-AP 
3’UTR, and that this inhibition was abrogated in the 
absence of such sequences [18].  Based on this study, it 
is tempting to conclude that the inhibition of TTP 
expression is a pre-requisite for the development of 
HPV-induced cervical cancer.  However, it is also 
possible that infection by HPV viruses or the expression 
of oncogenic factors directly reduce TTP levels, 
resulting in cell transformation. Testing these 
possibilities experimentally will help to define the exact 
role of TTP in malignant transformation. 
 
In conclusion, the work by Sanduja et al., and the recent 
studies described above provide provocative evidence 
that besides being a potent anti-inflammatory factor 
[23], TTP could suppress tumor growth by promoting 
the expression of factors that activate senescence and/or 
by decreasing the abundance of anti-apoptotic proteins.  
The identification of a link between TTP expression and 
the E6-induced cell transformation provides new 
insights into the molecular mechanism by which HPV 
16 or 18 viruses cause cervical cancer.  In addition, the 
new evidence points to TTP as a therapeutic target in 
future strategies to combat HPV-induced malignancies 
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